Contineum Therapeutics Reports Second Quarter 2026 Financial Results and Reaffirms Clinical Development Milestones Across Inflammatory and Fibrotic Disease Pipeline
Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing differentiated small-molecule therapies for inflammatory and fibrotic diseases with significant unmet medical needs, has announced its financial results for the second quarter ended June 30, 2026, while reaffirming progress across its clinical development programs. The company highlighted continued advancement of its lead investigational candidate, PIPE-791, expansion of its global Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF), and important milestones achieved through its collaboration with Johnson & Johnson.
Alongside its operational progress, Contineum also outlined strategic changes to its research organization, emphasizing a sharper focus on programs with the highest potential for clinical and commercial success. Management noted that the company’s current financial position provides a cash runway extending through mid-2029, allowing it to support ongoing clinical development while maintaining disciplined capital allocation.
Advancing the Global PROPEL-IPF Phase 2 Trial
The centerpiece of Contineum’s development strategy remains PROPEL-IPF, the company’s global Phase 2 clinical trial evaluating PIPE-791 as a potential treatment for idiopathic pulmonary fibrosis, a progressive and often fatal lung disease characterized by irreversible scarring of lung tissue.
Chief Executive Officer Carmine Stengone stated that the company continues to expand the trial’s global footprint, with more than 55 clinical sites now activated across eight countries. The increasing number of participating sites is expected to support consistent patient enrollment and accelerate trial progress.
Idiopathic pulmonary fibrosis remains an area of considerable unmet medical need. Current treatment options can slow disease progression in some patients but generally do not stop or reverse lung fibrosis. Consequently, there remains significant demand for new therapies capable of improving lung function, slowing disease progression, and enhancing quality of life.
By broadening its international clinical network, Contineum aims to recruit approximately 324 patients into the study, positioning the program to generate robust efficacy and safety data.
PROPEL-IPF Trial Design
The PROPEL-IPF study is a 26-week, randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics of once-daily oral PIPE-791.
Participants enrolled in the study are adults diagnosed with idiopathic pulmonary fibrosis. Patients are randomly assigned to receive either PIPE-791 or placebo throughout the treatment period.
The primary efficacy endpoint measures the change from baseline through Week 26 in forced vital capacity (FVC), a widely accepted indicator of lung function and disease progression in IPF clinical trials.
Secondary objectives include evaluating the safety profile of PIPE-791, monitoring adverse events, assessing pharmacokinetic characteristics, and exploring additional measures of respiratory function and clinical outcomes.
The company initiated patient dosing during the first quarter of 2026 and expects enrollment to continue steadily as additional clinical sites become operational.
Johnson & Johnson Advances PIPE-307 Program
Contineum also highlighted progress achieved through its partnership with Johnson & Johnson involving JNJ-5120 (formerly PIPE-307).
During June 2026, Johnson & Johnson completed enrollment in the Phase 2 MOONLIGHT-1 clinical trial, which is evaluating the investigational therapy as a monotherapy for adults living with major depressive disorder (MDD).
The randomized, double-blind, placebo-controlled proof-of-concept study enrolled 107 adult participants.
Completion of enrollment represents an important milestone in the collaboration and moves the program closer to generating clinical efficacy and safety data that may help determine future development strategies.
Major depressive disorder remains one of the most prevalent psychiatric illnesses worldwide, affecting millions of individuals and contributing substantially to disability, healthcare costs, and reduced quality of life. Despite numerous available antidepressants, many patients continue to experience inadequate symptom control or treatment-resistant disease, highlighting the need for therapies with novel mechanisms of action.
Positive Results from Phase 1b Chronic Pain Study
Earlier this year, Contineum reported encouraging topline data from an exploratory Phase 1b clinical trial evaluating PIPE-791 as a potential non-opioid treatment for chronic osteoarthritis pain and chronic low back pain.
The study successfully achieved its primary objective by demonstrating that PIPE-791 was generally safe and well tolerated.
According to the company, adverse events observed during the study were generally consistent with those reported in previous PIPE-791 clinical trials.
In addition to favorable safety findings, investigators observed encouraging efficacy trends.
Patients receiving PIPE-791 generally demonstrated greater numerical improvements in pain scores from baseline compared with patients receiving placebo.
Although the trial was exploratory and not powered for definitive efficacy conclusions, the results provide additional support for continued clinical investigation of PIPE-791 as a potential non-opioid therapy for chronic pain conditions.
Given ongoing concerns regarding opioid dependence, addiction, and overdose, development of effective non-opioid pain treatments remains a major priority across healthcare systems worldwide.
Research Strategy Becomes More Focused
Alongside its clinical progress, Contineum announced important organizational changes designed to sharpen its research focus.
The company has streamlined its discovery research programs to prioritize development of therapies targeting inflammatory and fibrotic diseases.
As part of this strategic realignment, Contineum implemented a limited workforce reduction within its research organization.
The restructuring also includes the departure of Chief Scientific Officer Daniel Lorrain, Ph.D.
Management emphasized that these actions are intended to concentrate scientific, translational, and clinical development resources on programs offering the highest probability of clinical success and long-term value creation.
CEO Carmine Stengone explained that the company remains committed to advancing its strongest pipeline assets while carefully managing financial resources.
Leadership Expresses Appreciation
While discussing the organizational changes, Stengone acknowledged Dr. Lorrain’s contributions to the company.
He noted that Lorrain played an important role in founding Contineum and helping build its scientific organization into its current form.
The CEO also expressed appreciation to the broader research team for its continued commitment to developing innovative therapies for patients living with serious inflammatory and fibrotic diseases.
According to management, the company’s future efforts will emphasize efficient resource allocation while preserving scientific excellence.
Financial Position Remains Strong
Contineum reported a strong financial position entering the second half of 2026.
As of June 30, 2026, the company held $236.6 million in cash, cash equivalents, and marketable securities.
Management believes these resources will be sufficient to fund planned operations through mid-2029, extending approximately one year beyond the anticipated completion of the ongoing Phase 2 PROPEL-IPF trial.
This financial flexibility allows Contineum to continue advancing its clinical programs without immediate financing requirements while maintaining strategic optionality for future pipeline investments.
Research and Development Spending Reflects Pipeline Priorities
Research and development expenses totaled $12.7 million during the second quarter of 2026, representing a 10% decrease compared with the same period in 2025.
The reduction primarily reflects:
- Completion of the PIPE-307 VISTA clinical trial
- Lower expenses associated with the PIPE-791 chronic pain program
These savings were partially offset by increased investments supporting:
- The ongoing PIPE-791 IPF development program
- Higher employee-related costs
The spending profile illustrates the company’s strategic shift toward prioritizing later-stage clinical development activities while reducing expenditures on completed programs.
General and Administrative Expenses Increase
General and administrative expenses increased to $4.7 million, representing a 23% year-over-year increase.
Management attributed the higher costs primarily to:
- Increased stock-based compensation
- Higher employee-related expenses
Despite the increase, overall administrative spending remains relatively modest compared with research investments, reflecting continued focus on operational efficiency.
Net Loss Improves
For the second quarter of 2026, Contineum reported a net loss of $15.2 million, compared with $16.0 million during the same period in 2025.
The modest improvement reflects lower research expenditures and disciplined expense management while the company continues investing heavily in clinical development.
As is typical for clinical-stage biotechnology companies without commercial products, Contineum continues to operate at a loss while funding research, regulatory, and development activities necessary to advance its investigational therapies toward potential regulatory approval.
Positioned for Long-Term Clinical Progress
Contineum enters the second half of 2026 with multiple important milestones already achieved and several additional catalysts expected over the coming years.
The expansion of the global PROPEL-IPF trial, completion of enrollment in Johnson & Johnson’s MOONLIGHT-1 study, encouraging early chronic pain data for PIPE-791, and a financial runway extending into 2029 collectively position the company to continue executing its long-term development strategy.
By concentrating resources on inflammatory and fibrotic diseases—areas where significant unmet medical needs remain—Contineum aims to maximize the potential of its lead programs while maintaining financial discipline. As patient enrollment continues across the PROPEL-IPF study and additional clinical data emerge from both internal and partnered programs, the company expects to build further evidence supporting the therapeutic potential of its differentiated small-molecule pipeline.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for major depressive disorder.